TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00981084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: armodafinil
Description: Half of the patients will be randomized to receive a single oral dose of placebo prior to the first testing session. After a washout period of one week, they will then receive 250mg of armodafinil prior to a second testing session (P/A group). The other half of patients will be randomized to receive the active drug first. After a washout period of one week, they will receive the placebo prior to a second testing session (A/P group). As plasma levels of armodafinil peak between 2-4 hours after administration, participants will be asked to take a single 250mg capsule 2 hours prior to the scheduled testing sessions.
Study: NCT01944865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Training
Description: The interval training group consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Training
Description: The riders of intermittent training group completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery.
Study: NCT02479230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine
Description: Given ID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT01735890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg
Description: single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg
Description: single dose
Study: NCT04062357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 5% spray
Description: Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks.
Study: NCT00842140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive
Description: oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive plus spironolactone
Description: The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive plus metformin
Description: Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin
Study: NCT04197713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study: NCT03512652

Intervention type: DEVICE
Group type: OTHER
Intervention: Patello
Description: The Patello is a new intervention device which mobilizes the Patella passively and continuously in cranial-caudal direction to increase Patella mobility.
Study: NCT04168554

Intervention type: DEVICE
Intervention: Telemedicine
Description: Patient is examined using telemedicine
Study: NCT04718428

Intervention type: DIAGNOSTIC_TEST
Intervention: Nail Ultrasonography
Description: The MyLab 60 (Esaote Biomedica Genoa, Italy) device and linear probe were used. Nails were examined in B-mode grayscale and power Doppler.

Intervention type: DIAGNOSTIC_TEST
Intervention: Nail Ultrasonography
Description: The MyLab 60 (Esaote Biomedica Genoa, Italy) device and linear probe were used. Nails were examined in B-mode grayscale and power Doppler.
Study: NCT01394393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential-Cognitive Therapy for Obesity
Description: Is a relatively short-term, integrated, patient oriented approach that focuses on individual discovery (Riva, Bacchetta, Baruffi, Rinaldi, \& Molinari, 1998, 1999; Riva et al., 2000). It shares with the cognitive-behavioral approach proposed by Cooper and colleagues the use of a combination of cognitive and behavioral procedures to help the patient identify and change the maintaining mechanisms (Cooper et al., 2003). However, it considers morbid obesity as a peculiar form of addiction. So, as in the cognitive-behavioral treatment of addictions (Carroll et al., 1994) the two main goals are the functional analysis of the maintaining mechanisms and the required skill training (relapse prevention).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral cognitive Treatment
Description: Therapists will follow a detailed manual that outlined the content of each session. This manual was based on the cognitive-behavioral treatment approach described by Cooper and colleagues (Cooper \& Fairburn, 2002; Cooper et al., 2003). It was developed during a year of intensive pilot work and adapted to the in-patient setting. Patients will be taught to self-monitor their food intake and eating patterns and thoughts, as well as the circumstances and environment surrounding eating (e.g. whether eating alone or with others, speed of eating, and place of eating). Patients will also be taught to identify problems in eating, mood, and thinking patterns and to gradually develop alternative patterns.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Nutritional groups (NT)
Description: 5 weekly nutritional treatment based on the LEARN manual (Brownell, 1985), whose goal will be to provide practical guidelines for the self-monitoring of eating and lessons on nutrition (e.g stressing gradual weight loss with the caloric restriction achieved largely by reductions in fat intake), plus a low-calorie diet (1,200 kcal/day) and physical training (30 min of walking two times a week as a minimum).
Study: NCT02245958

Intervention type: OTHER
Intervention: No Intervention
Description: No treatment (intervention) was administered.

Intervention type: OTHER
Intervention: No Intervention
Description: No treatment (intervention) was administered.
Study: NCT02626780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GID SVF-2
Description: Comparison of the number of hairs before and after treatment of autologous adipose-derived SVF as a percentage increase or decrease in growth.
Study: NCT02821403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clear lens with regular coating

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clear lens with regular coating

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: regular coating lens with yellow tint

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: regular coating lens with yellow tint

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clear lens with blue-light blocking coating

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clear lens with blue-light blocking coating
Study: NCT01855776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants, employers, and/or charities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants, employers, and/or charities.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants, employers, and/or charities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Incentives
Description: Incentives will be awarded to participants for meeting specified weekly step goals as measured by a pedometer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charitable Incentives
Description: Incentives will be awarded to charities selected by participants should the latter meet specified weekly step goals measured by a pedometer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating.
Study: NCT00254202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03331198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017 (lisocabtagene maraleucel)
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017 (lisocabtagene maraleucel)
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017 (lisocabtagene maraleucel)
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging anticancer therapy for disease control. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017 (lisocabtagene maraleucel) + ibrutinib
Description: Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started as soon as possible after eligibility is confirmed. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCAR017 (lisocabtagene maraleucel) + venetoclax
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants will receive venetoclax as bridging anticancer therapy on a weekly ramp up dosing schedule until stopping one day prior to lymphodepletion. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection, and the day after infusion venetoclax will be re-initiated.
Study: NCT04157517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp Alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp Alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp Alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp Alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp Alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab intravenous infusion.
Study: NCT01540487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linagliptin/metformin(high dose)
Description: patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (High dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/metformin(low dose)
Description: patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (Low dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
Study: NCT00208169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Study: NCT05268783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30
Description: Quality of life questionnaire that has to be completed every 6 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-GI.NET21
Description: Quality of life questionnaire that has to be completed every 6 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Satisfaction survey
Description: Questionnaire regarding satisfaction of care that has to be completed on Day 1.
Study: NCT00445172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E0302 (mecobalamin)
Description: Intramuscular injection, mecobalamin twice a week.
Study: NCT02842580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 FLUOROURACYL
Description: Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as a 2 hr infusion.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days. For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
Study: NCT04032678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Schiller Defigard Touch 7 - DGT7, Schiller Medical, France
Description: Cardioversion with a pulsed biphasic waveform

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA
Description: Cardioversion with a biphasic truncated exponential waveform
Study: NCT03265496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical exam
Description: Clinical exam is performed before treatment start

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Description: Liquid biopsy will be performed at baseline and every 3 cycles of chemotherapy until progression disease

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic exam
Description: Diagnostic exam (biopsy and imagery exam) will be performed at baseline if not previously done or incompletely done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1st line treatment
Description: 1st line chemotherapy (chemotherapy or EGFR targeted therapy) will be performed until progression disease.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tumor evaluation
Description: Tumor evaluation will be performed every 3 cycles of chemotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy will be performed at the end of study, after progression disease, if a mutation of EGFR is detected in tumor DNA.
Study: NCT01475383

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03654746
Description: 20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: once daily dosing of placebo capsules following the dosing scheme described in 1.1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily dosing of placebo capsules following the dosing scheme described in 1.1
Study: NCT02842580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 FLUOROURACYL
Description: Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as a 2 hr infusion.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days. For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acide folinique
Description: 200 mg/m² if Elvorine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acide folinique
Description: 200 mg/m² if Elvorine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Irinotecan is administered IV at a dose of 180 mg/m² over 90 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with irinotecan.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: Irinotecan is administered IV at a dose of 180 mg/m² over 90 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with irinotecan.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is administered IV at a dose of 85 mg/m² over 120 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with oxaliplatin.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days.
Study: NCT01475383

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-03654746
Description: 20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
Study: NCT02842580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin is administered IV at a dose of 85 mg/m² over 120 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with oxaliplatin.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capécitabine
Description: For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capécitabine
Description: For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
Study: NCT03355742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE
Description: Subjects who received XIENCE family stent systems will be included.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPT
Description: 1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.
Study: NCT02842580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab is administered IV at a dose of 5 mg/kg over 90 min at cycle 1, then 60 min at cycle 2 and 30 min in subsequent cycles. Bevacizumab is administered every 2 weeks before the start of chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Bevacizumab is administered IV at a dose of 5 mg/kg over 90 min at cycle 1, then 60 min at cycle 2 and 30 min in subsequent cycles. Bevacizumab is administered every 2 weeks before the start of chemotherapy
Study: NCT01998802

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator EBI-005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator